The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in solid tumors: Data-mining of 1,382 electronic patient records.
 
Mathilde Beaufils
No Relationships to Disclose
 
Vincent Amodru
Research Funding - Ipsen
 
Manuel Tejeda
No Relationships to Disclose
 
Brice Chanez
No Relationships to Disclose
 
Anne Sophie Chretien
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - NKp30 expression predicts clinical outcome in AML patients with intermediate prognosis EP17305151.7, 2017 Altered NK maturation in patients with Acute Myeloid Leukemia EP17305235.8, 2017 NKp46 for outcome in AML patients WO2015144841 A1, 2015
 
Gwenaelle Gravis
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); IPSEN (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Speakers' Bureau - Amgen (Inst); Astellas Pharma (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Sanofi/Aventis (Inst)
Research Funding - BMS (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi
 
Anne Madroszyk
No Relationships to Disclose
 
Anthony Goncalves
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst)
 
Aaron E. Lisberg
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Leica Biosystems; Lilly; MorphoSys; Novartis; Novocure; Oncocyte; Pfizer; Sanofi/Regeneron
Research Funding - AstraZeneca; Calithera Biosciences; Daiichi Sankyo; Dracen; WindMIL
 
Daniel Olive
Stock and Other Ownership Interests - Alderaan Biotechnology; GlaxoSmithKline; Imcheck Therapeutics
Research Funding - Imcheck Therapeutics
 
Louis Tassy
No Relationships to Disclose
 
Frédéric Castinetti
No Relationships to Disclose
 
Philippe Rochigneux
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Novartis
Research Funding - Novartis (Inst)